Promino Nutritional Sciences Inc. Launches Second Preclinical Study Targeting Reduction of Muscle Loss in Breast and Prostate Cancer Patients Undergoing Chemotherapy
Promino Nutritional Sciences (CSE: MUSL, OTC: MUSLF) has initiated its second preclinical study to evaluate how its patented essential amino acid (EAA) blend affects muscle preservation during chemotherapy for breast and prostate cancer patients.
The research, led by Dr. Patrick Gunning, Chief Scientific Advisor to Promino and Professor of Medicinal Chemistry and Molecular Therapeutics at the University of Toronto and University of Glasgow, will use murine models to study the blend's effectiveness in preventing cachexia (severe muscle loss) during chemotherapy treatment.
The study targets breast cancer, affecting over 2.3 million women annually, and prostate cancer, impacting 1.4 million men yearly. The company's EAA formulation, developed by Dr. Robert Wolfe of the University of Arkansas, is designed to stimulate muscle protein synthesis during metabolic stress. Results from these preclinical trials will guide future human studies and potential clinical collaborations with North American oncology institutions.
Promino Nutritional Sciences (CSE: MUSL, OTC: MUSLF) ha avviato il suo secondo studio preclinico per valutare come la sua miscela brevettata di aminoacidi essenziali (EAA) influisca sulla preservazione muscolare durante la chemioterapia per pazienti affetti da cancro al seno e alla prostata.
La ricerca, guidata dal Dr. Patrick Gunning, Consigliere Scientifico Capo di Promino e Professore di Chimica Medicinale e Terapie Molecolari presso l'Università di Toronto e l'Università di Glasgow, utilizzerà modelli murini per studiare l'efficacia della miscela nel prevenire la cachessia (perdita muscolare severa) durante il trattamento chemioterapico.
Lo studio si concentra sul cancro al seno, che colpisce oltre 2,3 milioni di donne ogni anno, e sul cancro alla prostata, che impatta 1,4 milioni di uomini ogni anno. La formulazione di EAA dell'azienda, sviluppata dal Dr. Robert Wolfe dell'Università dell'Arkansas, è progettata per stimolare la sintesi proteica muscolare durante lo stress metabolico. I risultati di questi studi preclinici guideranno futuri studi su esseri umani e potenziali collaborazioni cliniche con istituzioni oncologiche nordamericane.
Promino Nutritional Sciences (CSE: MUSL, OTC: MUSLF) ha iniciado su segundo estudio preclínico para evaluar cómo su mezcla patentada de aminoácidos esenciales (EAA) afecta la preservación muscular durante la quimioterapia en pacientes con cáncer de mama y próstata.
La investigación, dirigida por el Dr. Patrick Gunning, Asesor Científico Principal de Promino y Profesor de Química Medicinal y Terapias Moleculares en la Universidad de Toronto y la Universidad de Glasgow, utilizará modelos murinos para estudiar la efectividad de la mezcla en la prevención de la caquexia (pérdida muscular severa) durante el tratamiento de quimioterapia.
El estudio se centra en el cáncer de mama, que afecta a más de 2.3 millones de mujeres anualmente, y el cáncer de próstata, que impacta a 1.4 millones de hombres cada año. La formulación de EAA de la empresa, desarrollada por el Dr. Robert Wolfe de la Universidad de Arkansas, está diseñada para estimular la síntesis de proteínas musculares durante el estrés metabólico. Los resultados de estos ensayos preclínicos guiarán futuros estudios en humanos y posibles colaboraciones clínicas con instituciones oncológicas de América del Norte.
프로미노 영양 과학 (CSE: MUSL, OTC: MUSLF)는 유방암 및 전립선암 환자의 화학요법 중 근육 보존에 미치는 특허받은 필수 아미노산(EAA) 혼합물의 영향을 평가하기 위해 두 번째 전임상 연구를 시작했습니다.
이 연구는 패트릭 건닝 박사가 이끌며, 프로미노의 수석 과학 고문이자 토론토 대학교 및 글래스고 대학교의 의약 화학 및 분자 치료학 교수입니다. 이 연구는 마우스 모델을 사용하여 화학요법 치료 중 캐시엑시아(심각한 근육 손실)를 예방하는 혼합물의 효과를 연구할 것입니다.
이 연구는 매년 230만 명 이상의 여성에게 영향을 미치는 유방암과 매년 140만 명의 남성에게 영향을 미치는 전립선암을 대상으로 하고 있습니다. 로버트 울프 박사가 아칸소 대학교에서 개발한 회사의 EAA 제형은 대사 스트레스 동안 근육 단백질 합성을 자극하도록 설계되었습니다. 이 전임상 시험의 결과는 향후 인간 연구 및 북미 종양학 기관과의 잠재적 임상 협력을 안내할 것입니다.
Promino Nutritional Sciences (CSE: MUSL, OTC: MUSLF) a lancé sa deuxième étude préclinique pour évaluer comment son mélange breveté d'acides aminés essentiels (EAA) affecte la préservation musculaire pendant la chimiothérapie chez les patientes atteintes de cancer du sein et les patients atteints de cancer de la prostate.
La recherche, dirigée par le Dr. Patrick Gunning, Conseiller Scientifique Principal de Promino et Professeur de Chimie Médicale et de Thérapies Moléculaires à l'Université de Toronto et à l'Université de Glasgow, utilisera des modèles murins pour étudier l'efficacité du mélange dans la prévention de la cachexie (perte musculaire sévère) pendant le traitement de chimiothérapie.
L'étude vise le cancer du sein, qui touche plus de 2,3 millions de femmes chaque année, et le cancer de la prostate, qui impacte 1,4 million d'hommes chaque année. La formulation d'EAA de l'entreprise, développée par le Dr. Robert Wolfe de l'Université de l'Arkansas, est conçue pour stimuler la synthèse des protéines musculaires pendant le stress métabolique. Les résultats de ces essais précliniques guideront les futures études sur l'homme et les collaborations cliniques potentielles avec des institutions oncologiques nord-américaines.
Promino Nutritional Sciences (CSE: MUSL, OTC: MUSLF) hat seine zweite präklinische Studie initiiert, um zu bewerten, wie sich seine patentierte Mischung aus essentiellen Aminosäuren (EAA) auf den Erhalt der Muskulatur während der Chemotherapie bei Brust- und Prostatakrebspatienten auswirkt.
Die Forschung, geleitet von Dr. Patrick Gunning, Chief Scientific Advisor von Promino und Professor für Medizinische Chemie und Molekulare Therapeutik an der University of Toronto und der University of Glasgow, wird Mausmodelle verwenden, um die Wirksamkeit der Mischung bei der Prävention von Kachexie (schwerer Muskelverlust) während der Chemotherapie zu untersuchen.
Die Studie richtet sich an Brustkrebs, der jährlich über 2,3 Millionen Frauen betrifft, und Prostatakrebs, der jährlich 1,4 Millionen Männer betrifft. Die EAA-Formulierung des Unternehmens, entwickelt von Dr. Robert Wolfe von der University of Arkansas, soll die Muskelproteinsynthese während metabolischen Stresses anregen. Die Ergebnisse dieser präklinischen Studien werden zukünftige Studien am Menschen und potenzielle klinische Kooperationen mit nordamerikanischen Onkologieeinrichtungen leiten.
- Targeting large market opportunity with 3.7 million combined breast and prostate cancer patients annually
- Product developed by recognized experts in amino acid science
- Potential to improve chemotherapy treatment tolerance and recovery outcomes
- Still in early preclinical stage with no human trial data
- No revenue generation from this product line yet
- Success in murine models may not translate to human efficacy
- Research to explore Promino's patented amino acid blend in addressing treatment-related muscle wasting in two of the most prevalent cancers among women and men
- Study led by Dr. Patrick Gunning, Professor of Medicinal Chemistry and Molecular Therapeutics, University of Toronto and University of Glasgow
Burlington, Ontario--(Newsfile Corp. - April 14, 2025) - Promino Nutritional Sciences Inc. (CSE: MUSL) (OTC Pink: MUSLF) (FSE: 93X) (the "Company" or "Promino") is pleased to announce the launch of its second round of preclinical studies evaluating the effects of Promino, a patented essential amino acid (EAA) blend, on muscle preservation and systemic health during chemotherapy treatment for breast and prostate cancer - the most commonly diagnosed cancers in women and men, respectively.
The preclinical trials will be conducted using murine models and aim to provide critical insights into the role of Promino's clinically formulated EAA blend in counteracting the severe muscle loss (cachexia) often associated with chemotherapy. The studies are being led by Dr. Patrick Gunning, a globally recognized medicinal chemist and Chief Scientific Advisor to Promino.
Addressing a Widespread and Underserved Need in Oncology Support
Breast cancer affects more than 2.3 million women globally each year[1], while prostate cancer impacts over 1.4 million men annually[2]. Despite advances in oncology, many patients suffer significant declines in muscle mass and function during chemotherapy, impairing both treatment tolerance and recovery outcomes.
"These preclinical studies represent a critical step toward understanding how targeted amino acid formulations can support patients undergoing highly demanding chemotherapy protocols," said Dr. Patrick Gunning, Chief Scientific Advisor to Promino. "Preserving muscle mass and function is not only about quality of life, it may also influence treatment outcomes and recovery trajectories. We're excited to be advancing this vital research."
Rooted in Breakthrough Science by Leading Researchers
Promino's formulation was developed by Dr. Robert Wolfe of the University of Arkansas, leaders in amino acid science and pioneers in the study of muscle metabolism. Their patented EAA blend is optimized to stimulate muscle protein synthesis, even in the face of metabolic stress such as surgical recovery and extreme metabolic deficit.
Toward a Dedicated Oncology Line for Patients and Providers
This latest preclinical initiative will not only help inform Promino's future clinical roadmap but also support the development of a Promino line specifically tailored to oncology care with the goal of providing patients, healthcare systems, and medical professionals with targeted nutritional tools to help combat treatment-related muscle wasting.
"This is a landmark moment for Promino and the science behind our proprietary amino acid blend," said Vito Sanzone, CEO of Promino. "We are uniquely positioned to lead the intersection of clinical nutrition and cancer care. Our goal is to deliver Promino as a precision nutritional therapy that supports better treatment tolerance, faster recovery, and stronger quality of life."
Next Steps
The new preclinical studies follow encouraging initial data and are designed to meet rigorous scientific standards. Results will inform future human trials and potential clinical collaborations with leading oncology institutions in North America.
For more information on Promino's research pipeline and commitment to innovation in clinical nutrition, visit www.drinkpromino.com.
About Promino
Promino is an innovative and research driven Canadian nutraceutical company specializing in the development of patented and science-based products for the global consumer packaged goods market, with a portfolio focused specifically on muscle health. Promino's lead product, Rejuvenate Muscle™ Activator, is a patented proprietary formulation that is clinically proven to assist in the building, rebuilding, restoration and rejuvenation of natural muscle mass. Promino also offers Promino™, an elite performance supplement for both professional and amateur athletes to accelerate muscle recovery, build strength and accelerate recovery from injury. Promino was founded in 2015 and is located in Burlington, Ontario.
For more information about Rejuvenate Muscle™ Activator and where to purchase, visit www.rejuvenatemuscle.com.
Promino™ - NSF Certified for Sport® brand ambassadors include NHL Stanley Cup™ Champion Jack Eichel of the Vegas Golden Knights and MLB Legend and Toronto Blue Jays 6x All-Star José Bautista.
To learn more about Promino, visit www.drinkpromino.com.
Forward-Looking Statements
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. All statements that address activities, events, or developments that the Company expects or anticipates will, or may, occur in the future, are forward-looking statements, including statements regarding the Company's business prospects, potential growth in the functional beverage market, future trends, plans and strategies. In some cases, forward looking statements are preceded by, followed by, or include words such as "may", "will," "would", "could", "should", "believes", "estimates", "projects", "potential", "expects", "plans", "anticipates", "continues", or the negative of those words or other similar or comparable words. In preparing the forward-looking statements in this news release, the Company has applied several material assumptions, including, but not limited to, that protein supplement market growth will continue as anticipated by the Company, and that general business and economic conditions will not change in a materially adverse manner. These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors.
No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
For further information about Promino:
Vito Sanzone, CEO, vsanzone@drinkpromino.com, 289-348-1970 ext. 222
Marc Charbin, Investor Relations, marc.charbin@loderockadvisors.com, 416-467-5229
[1] Current and future burden of breast cancer: Global statistics for 2020 and 2040 - PMC
[2] The Lancet Commission on prostate cancer: planning for the surge in cases - The Lancet
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/248388
FAQ
What is the purpose of Promino's new preclinical study for MUSLF stock?
How many patients are affected by the cancers targeted in MUSLF's new study?
Who is leading MUSLF's preclinical trials for cancer patients?
What is the next step after MUSLF's preclinical cancer studies?
What specific condition does MUSLF's amino acid blend target in cancer patients?
